GlassScriptPhysician profile
Benjamin L Stewart
NPI 1558587253
$7,125.57
in general payments reported to CMS, 2019-2025
33 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $570 · 2021: $845 · 2022: $1,238 · 2023: $1,433 · 2024: $1,508 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,228.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,600.78 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $865.18 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $651.57 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $608.41 | 2020-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $485.12 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $362.13 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $294.51 | 2020-2024 | Prolia, Evenity, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $291.46 | 2022-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $273.25 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $222.95 | 2020-2024 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Pfizer INC. | $183.35 | 2019-2025 | |
| Exact Sciences Corporation | $176.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $145.83 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $129.09 | 2024-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $116.73 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $87.80 | 2019-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $75.28 | 2022-2024 | Rexulti |
| Sanofi Pasteur INC. | $69.54 | 2020-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $64.18 | 2022 | |
| Ardelyx, INC. | $43.39 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $42.93 | 2024-2025 | Voquezna |
| Viatris Specialty LLC | $37.00 | 2025 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $36.94 | 2021 | |
| Astellas Pharma US INC | $34.78 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $33.11 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $31.86 | 2021 | |
| Xeris Pharmaceuticals, INC. | $30.94 | 2023-2024 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $27.42 | 2025 | Auvelity |
| Sonex Health, INC. | $26.56 | 2025 | Sx-One Microknife |
| Novartis Pharmaceuticals Corporation | $23.44 | 2025 | |
| Sumitomo Pharma America, INC. | $22.16 | 2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $18.71 | 2021 | |
| Cequr Corporation | $12.40 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.